MONITORING FORCE   Report issue

For profit Phase 3
Founded: Germany (1995)

Organization Overview

First Clinical Trial
2010
NCT01120405
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

sevoflurane (ultane) (1 trial)

xenon xe-133 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2